{'fraction_non_alphanumeric': 0.03225806451612903, 'fraction_numerical': 0.0035842293906810036, 'mean_word_length': 4.822916666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Lung cancer screening is cost effective, but only if done correctly.

The U.S. Preventive Services Task Force (USPSTF) gave lung cancer screening a B recommendation on the basis of the reductions in disease-specific mortality and all-cause mortality seen in the National Lung Screening Trial (NLST). The NLST does not consider cost or cost-effectiveness in its recommendations. This cost-effectiveness analysis suggests that screening is most cost-effective for current smokers, for patients in their 60s, and for those who are at higher risk of lung cancer.